Abstract
Despite favourable mortality rates, up to 30% of PTC patients suffer recurrence. The current widely used circulating biomarker, thyroglobulin (Tg), is unreliable in up to 25% of these patients. Therefore, a systemic biomarker of PTC may circumvent some of the issues associated with Tg, and may also be an adjunct to FNA in the diagnosis of PTC. We aimed to measure the levels of plasma miRNAs which are over-expressed in PTC tissue, and to demonstrate a reduction in their levels after removal of macroscopic malignant tissue.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
